AstraZeneca, Daiichi Sankyo breast cancer drug Trastuzumab Deruxtecan shows promise

The treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic breast cancer, the two companies said in a joint statement.

U.S: British drugmaker AstraZeneca and Japan's Daiichi Sankyo said on Wednesday their experimental treatment for breast cancer met its key goal in a mid-stage study, bolstering their defences in a highly competitive oncology market.

Read Also: AstraZeneca Q1 sales beat estimates on cancer drugs

The treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic breast cancer, the two companies said in a joint statement.

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biopharmaceutical company. In 2013, it moved its headquarters to Cambridge, UK. The company has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.

Read Also: Astrazeneca, Merck wins EU nod for Lynparza to treat breast cancer